Hypertension in HIV positive patients

Czech version

Authors: Z. Pozdíšek ¹; O. Ludka ¹; V. Musil ¹; J. Vlašínová ¹; S. Snopková ²; P. Lokaj ¹; J. Špinar ¹
Authors‘ workplace: Interní kardiologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Jindřich Špinar, CSc., FESC ¹; Klinika infekčních chorob Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Petr Husa, CSc. ²
Published in: Vnitř Lék 2008; 54(6): 615-617
Category: Original Contributions

Overview

Survival of HIV-positive patients on highly active antiretroviral therapy (HAART) has significantly improved. Although traditional heart complications of the infection such as pericarditis or myocarditis has become rather rare owing to the therapy, wide range of metabolic abnormalities have been described. We focused on the evaluation of prevalence of hypertension among HIV positive patients with respect to their high cardiovascular risk. We examined 40 HIV positive patients (28 males and 12 females) followed in AIDS center in Brno. All probands underwent 24-hour ambulatory blood pressure monitoring as a part of their cardiological examination. 40 age- and gender-matched healthy controls were recruited. We evaluated the average value of systolic (SBP) and diastolic (DBP) blood pressure as well as the average value of heart rate (HR) within 24 hours of monitoring. Following values were found in the group of healthy controls: SBP 124.1 ± 8.6 mm Hg, DBP 71.6 ± 6.9 mm Hg and HR 67.9 ± 9.7/min. HIV positive patients presented with the following values: SBP 118.5 ± 9.3 mm Hg, DBP 76.8 ± 5.7 mm Hg a HR 78.6 ± 9.7/min. All the differences were statistically significant at p < 0.05. We diagnosed 14 patients with hypertension defined as SBP higher than 125 mm Hg and/or DBP higher than 80 mm Hg in both of the groups. Prevalence of hypertension in HIV positive patients was comparable to that seen in healthy controls. HIV positive patients had lower SBP but higher DBP and HR.

Key words:
hypertension - HIV-positive patients - HAART

Sources

1. Fantoni M, Del Borgo C, Autore C. Evaluation and management of metabolit and coagulative disorders in HIV-infected patients receiving highly aktive antiretroviral therapy. AIDS 2003; 17(Suppl 1): S162-S169.

2. Calza L, Manfredi R, Chiodo F. Hyperlipidaemia in patients with HIV-1 infection receiving antiretroviral therapy: epidemiology, pathogenesis, clinical course and management. Int J Antimicrob Agents 2003; 22: 89-99.

3. Gazzaruso C, Bruno R, Garzaniti A et al. Hypertension among HIV patients: prevalence and relationship to insulin resistence and metabolic syndrome. J Hypertens 2003; 21: 1377-1382.

4. Sudano I, Spieker LE, Noll G et al. Cardiovascular disease in HIV infection. Am Heart J 2006; 151: 1147-1155.

5. Barbaro G, Fischer SD, Lipshultz SE. Pathogenesis of HIV-associated cardiovascular complications. Lancet Infect Dis 2001; 1: 115-124.

6. Honzikova N, Fiser B, Semrad B. Critical value of baroreflex sensitivity determined by spectral analysis in risk stratification after myocardial infarction. Laciny Clin Electrophysiol 2000; 23: 1965-1967.

7. La Rovere MT, Digger JT, Marcus FI et al. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Lancet 1998; 351: 478-484.

8. Guidelines Committee. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053.

9. Mattana J, Siegel FP, Sankaran RT et al. Absence of age-related increase in systolic blood pressure in ambulatory patients with HIV infection. Am J Med Sci 1999; 23: 232-237.

10. Bergersen BM, Sandvik L, Dunlop O et al. Prevalence of hypertension in HIV-positive patients on highly active retroviral therapy (HAART) compared with HAART-naive and HIV-negative controls: results from a Norwegian study of 721 patients. Eur J Clin Microbiol Infect Dis 2003; 22: 731-736.

11. Hadigan C, Meigs JB, Corcoran C et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001; 32: 130-139.

12. Sattler FR, Qian D, Louie S et al. Elevated blood pressure in subjects with lipodystrophy. AIDS 2001; 15: 2001-2010.

13. Lipshultz SE, Fischer SD, Lai WW et al. Cardiovascular risk factors, monitoring, and therapy for HIV-infected patients. AIDS 2003; 17(Suppl 1): S96-S122.

14. Gluck T, Degenhardt E, Scholmerich J et al. Autonomic neuropathy in patients with HIV: course, impact of disease stage, and medication. Clin Auton Res 2000; 10: 17-22.

15. Ruttimann S, Hilti P, Spinas GA et al. High frequency of human immunodeficiency virus-associated autonomic neuropathy and more severe involvement in advanced stages of human immunodeficiency virus disease. Arch Intern Med 1991; 151: 2441-2443.